ALSO NOTED: Medtronic earnings drop 89%; GSK buys back 2.7M shares;

> Medtronic's third-quarter earnings plummeted by 89 percent to $77 million because of charges on lawsuit settlements and acquisition costs, but even the adjusted profit beat Wall Street expectations. Report

> GlaxoSmithKline bought 2.7 million of its own shares as part of a stock buyback program authorized last May to boost value. Report

> AstraZeneca appointed Jean-Philippe Courtois, president of Microsoft International, as non-executive director. Report

> Ireland's Health Service Executive says it may buy drugs from international suppliers if domestic wholesalers don't absorb the cost of reduced profit margins instead of passing it along to pharmacies. Report

> Denmark's Pharmexa will cut 20 percent of its workforce after finding buyers for just 18.2 million of 69 million new shares of stock. Report

> Endo Pharmaceuticals and Penwest Pharmaceuticals say they will fight a generic version of their Opana ER pain drug planned by Actavis. Report

> Janssen Korea, a unit of Johnson & Johnson, says it plans to expand and modernize its plants in that country; this year it will spend more than $2 million on new equipment. Report

> Mistral Pharma won a deal to distribute six injectable generic drugs in Canada for an unidentified drug maker. Report

> Carl Icahn has cashed in his Genzyme chips and evidently gone looking for another game. Report

> FierceHealthcare asks: Would a new agency curb pharma marketing misdeeds? Editorial

And Finally... Living past 90 isn't rocket science: stop smoking, manage weight, control blood pressure, exercise regularly and avoid diabetes. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.